These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12566376)

  • 21. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms.
    Yarbrough WM; Mukherjee R; Stroud RE; Meyer EC; Escobar GP; Sample JA; Hendrick JW; Mingoia JT; Spinale FG
    J Cardiovasc Pharmacol; 2010 Apr; 55(4):408-16. PubMed ID: 20147844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.
    Lindsey ML; Zamilpa R
    Cardiovasc Ther; 2012 Feb; 30(1):31-41. PubMed ID: 20645986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.
    Spinale FG; Coker ML; Krombach SR; Mukherjee R; Hallak H; Houck WV; Clair MJ; Kribbs SB; Johnson LL; Peterson JT; Zile MR
    Circ Res; 1999 Aug; 85(4):364-76. PubMed ID: 10455065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways.
    Dixon JA; Gorman RC; Stroud RE; Mukherjee R; Meyer EC; Baker NL; Morita M; Hamamoto H; Ryan LP; Gorman JH; Spinale FG
    Circulation; 2011 Sep; 124(11 Suppl):S35-45. PubMed ID: 21911817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling.
    Wilson EM; Moainie SL; Baskin JM; Lowry AS; Deschamps AM; Mukherjee R; Guy TS; St John-Sutton MG; Gorman JH; Edmunds LH; Gorman RC; Spinale FG
    Circulation; 2003 Jun; 107(22):2857-63. PubMed ID: 12771000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MMP induction and inhibition in myocardial infarction.
    Lindsey ML
    Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function.
    Barlow SC; Doviak H; Jacobs J; Freeburg LA; Perreault PE; Zellars KN; Moreau K; Villacreses CF; Smith S; Khakoo AY; Lee T; Spinale FG
    Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H690-H699. PubMed ID: 28754718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling.
    Mukherjee R; Rivers WT; Ruddy JM; Matthews RG; Koval CN; Plyler RA; Chang EI; Patel RK; Kern CB; Stroud RE; Spinale FG
    Circulation; 2010 Jul; 122(1):20-32. PubMed ID: 20566951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of MMP/TIMP by HUVEC transplantation attenuates ventricular remodeling in response to myocardial infarction.
    Kwon JS; Kim YS; Cho AS; Cho HH; Kim JS; Hong MH; Jeong HY; Kang WS; Hwang KK; Bae JW; Jeong MH; Cho MC; Ahn Y
    Life Sci; 2014 Apr; 101(1-2):15-26. PubMed ID: 24560960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
    Hayashidani S; Tsutsui H; Shiomi T; Suematsu N; Kinugawa S; Ide T; Wen J; Takeshita A
    Circulation; 2002 Feb; 105(7):868-73. PubMed ID: 11854129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling.
    Villarreal FJ; Griffin M; Omens J; Dillmann W; Nguyen J; Covell J
    Circulation; 2003 Sep; 108(12):1487-92. PubMed ID: 12952845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution.
    Iyer RP; Patterson NL; Zouein FA; Ma Y; Dive V; de Castro Brás LE; Lindsey ML
    Int J Cardiol; 2015 Apr; 185():198-208. PubMed ID: 25797678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction.
    Doerries C; Grote K; Hilfiker-Kleiner D; Luchtefeld M; Schaefer A; Holland SM; Sorrentino S; Manes C; Schieffer B; Drexler H; Landmesser U
    Circ Res; 2007 Mar; 100(6):894-903. PubMed ID: 17332431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat.
    Gaertner R; Jacob MP; Prunier F; Angles-Cano E; Mercadier JJ; Michel JB
    J Mol Cell Cardiol; 2005 Jan; 38(1):193-204. PubMed ID: 15623436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice.
    Zavadzkas JA; Stroud RE; Bouges S; Mukherjee R; Jones JR; Patel RK; McDermott PJ; Spinale FG
    Circ Res; 2014 Apr; 114(9):1435-45. PubMed ID: 24637197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction.
    Kandalam V; Basu R; Abraham T; Wang X; Awad A; Wang W; Lopaschuk GD; Maeda N; Oudit GY; Kassiri Z
    Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1012-23. PubMed ID: 20675565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling.
    Lobb DC; Doviak H; Brower GL; Romito E; O'Neill JW; Smith S; Shuman JA; Freels PD; Zellars KN; Freeburg LA; Khakoo AY; Lee T; Spinale FG
    J Pharmacol Exp Ther; 2020 Nov; 375(2):296-307. PubMed ID: 32958629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction.
    Sahul ZH; Mukherjee R; Song J; McAteer J; Stroud RE; Dione DP; Staib L; Papademetris X; Dobrucki LW; Duncan JS; Spinale FG; Sinusas AJ
    Circ Cardiovasc Imaging; 2011 Jul; 4(4):381-91. PubMed ID: 21505092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.